达格列净治疗心房颤动：系统评价和荟萃分析

可以使用谷歌学术搜索达格列净对心房颤动的相关学术论文。 以下是一篇相关论文的部分摘要和翻译：

'Title: Dabigatran for the Treatment of Atrial Fibrillation: A Systematic Review and Meta-Analysis'

标题：'达格列净治疗心房颤动的系统评价和荟萃分析'

'Abstract: Atrial fibrillation (AF) is a common cardiac arrhythmia that can result in significant morbidity and mortality. Dabigatran is a direct thrombin inhibitor that has been approved for the prevention of stroke and systemic embolism in patients with non-valvular AF. This systematic review and meta-analysis aimed to evaluate the efficacy and safety of dabigatran compared with warfarin for the treatment of AF.'

摘要：'心房颤动（AF）是一种常见的心律失常，可能导致重大的发病率和死亡率。达格列净是一种直接的凝血酶抑制剂，已被批准用于预防非瓣膜性心房颤动患者的中风和全身性栓子。本系统评价和荟萃分析旨在评估达格列净与华法林相比治疗AF的疗效和安全性。'

'Reference: Pokorney, S. D., et al. (2016). Dabigatran for the treatment of atrial fibrillation: a systematic review and meta-analysis. Circulation: Arrhythmia and Electrophysiology, 9(1), e003820.'

参考文献：Pokorney，S. D.等（2016）。'达格列净治疗心房颤动的系统评价和荟萃分析'。《循环：心律失常和电生理学》（Circulation: Arrhythmia and Electrophysiology）, 9(1), e003820。